{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:06:53Z","timestamp":1789031213040,"version":"build-2803163510"},"reference-count":95,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,9,3]],"date-time":"2027-09-03T00:00:00Z","timestamp":1819929600000},"content-version":"am","delay-in-days":367,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA283313"],"award-info":[{"award-number":["R01CA283313"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Pharmacological Sciences"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.tips.2026.07.004","type":"journal-article","created":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T12:24:52Z","timestamp":1786191892000},"page":"959-978","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["STAT3 signaling inhibitors for cancer treatment"],"prefix":"10.1016","volume":"47","author":[{"given":"Rasaq","family":"Akinsola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6964-1602","authenticated-orcid":false,"given":"James","family":"Turkson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tips.2026.07.004_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2025.117076","article-title":"The effects of STAT3 acetylation on the transcriptional activity and tumorigenesis","volume":"240","author":"Yan","year":"2025","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.tips.2026.07.004_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.114629","article-title":"Ruxolitinib suppresses tumor growth in PTEN-deficient glioblastoma by inhibiting the STAT3-PDL1 axis-mediated the M2 polarization of macrophages","volume":"155","author":"Yao","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.tips.2026.07.004_bb0015","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.add2282","article-title":"STAT3 palmitoylation initiates a positive feedback loop that promotes the malignancy of hepatocellular carcinoma cells in mice","volume":"16","author":"Jiang","year":"2023","journal-title":"Sci. Signal."},{"key":"10.1016\/j.tips.2026.07.004_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mitoco.2024.01.001","article-title":"Structural determinants of mitochondrial STAT3 targeting and function","volume":"2","author":"Mari\u00e9","year":"2024","journal-title":"Mitochondrial. Commun."},{"key":"10.1016\/j.tips.2026.07.004_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2025.112048","article-title":"Post-translational modifications of Stat3: the state of the art","volume":"135","author":"Chen","year":"2025","journal-title":"Cell. Signal."},{"key":"10.1016\/j.tips.2026.07.004_bb0030","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s13045-021-01214-y","article-title":"STAT proteins: a kaleidoscope of canonical and non-canonical functions in immunity and cancer","volume":"14","author":"Awasthi","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.tips.2026.07.004_bb0035","first-page":"481","article-title":"The STAT3-VDAC1 axis modulates mitochondrial function and plays a critical role in the survival of acute myeloid leukemia cells","volume":"111","author":"Gil","year":"2026","journal-title":"Haematologica"},{"key":"10.1016\/j.tips.2026.07.004_bb0040","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.neo.2021.10.003","article-title":"STAT3 as a mediator of oncogenic cellular metabolism: pathogenic and therapeutic implications","volume":"23","author":"To\u0161i\u0107","year":"2021","journal-title":"Neoplasia"},{"key":"10.1016\/j.tips.2026.07.004_bb0045","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s11030-022-10490-w","article-title":"Screening of potent STAT3-SH2 domain inhibitors from JAK\/STAT compound library through molecular dynamics simulation","volume":"27","author":"Manoharan","year":"2023","journal-title":"Mol. Divers."},{"key":"10.1016\/j.tips.2026.07.004_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.106015","article-title":"(+)-Isocryptotanshinone derivatives and its simplified analogs as STAT3 signaling pathway inhibitors","volume":"127","author":"Shi","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.tips.2026.07.004_bb0055","doi-asserted-by":"crossref","first-page":"883","DOI":"10.2147\/OTT.S187777","article-title":"Cryptotanshinone inhibits esophageal squamous-cell carcinoma in vitro and in vivo through the suppression of STAT3 activation","volume":"12","author":"Ji","year":"2019","journal-title":"Onco. Targets Ther."},{"key":"10.1016\/j.tips.2026.07.004_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104661","article-title":"LYW-6, a novel cryptotanshinone derived STAT3 targeting inhibitor, suppresses colorectal cancer growth and metastasis","volume":"153","author":"Wang","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.tips.2026.07.004_bb0065","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.597520","article-title":"Napabucasin reduces cancer stem cell characteristics in hepatocellular carcinoma","volume":"11","author":"Li","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.tips.2026.07.004_bb0070","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00280-025-04770-z","article-title":"Napabucasin targets resistant triple negative breast cancer through suppressing STAT3 and mitochondrial function","volume":"95","author":"Yuan","year":"2025","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.tips.2026.07.004_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118329","article-title":"Discovery of a novel napabucasin derivative B16 as a potent STAT3 inhibitor for the treatment of triple-negative breast cancer","volume":"302","author":"Deng","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.tips.2026.07.004_bb0080","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ejmech.2018.10.067","article-title":"A novel series of napabucasin derivatives as orally active inhibitors of signal transducer and activator of transcription 3 (STAT3)","volume":"162","author":"Li","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.tips.2026.07.004_bb0085","doi-asserted-by":"crossref","first-page":"5678","DOI":"10.3390\/molecules28155678","article-title":"The anticancer effect of napabucasin (BBI608), a natural naphthoquinone","volume":"28","author":"Shao","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.tips.2026.07.004_bb0090","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/s13046-019-1289-6","article-title":"Napabucasin, a novel STAT3 inhibitor suppresses proliferation, invasion and stemness of glioblastoma cells","volume":"38","author":"Han","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.tips.2026.07.004_bb0095","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.3390\/medicina60101715","article-title":"Napabucasin inhibits proliferation and migration of glioblastoma cells (U87) by regulating JAK2\/STAT3 signaling pathway","volume":"60","author":"\u00dcnl\u00fc","year":"2024","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.tips.2026.07.004_bb0100","article-title":"Feasibility of the inhibitor development for cancer: a systematic approach for drug design","volume":"19","author":"Jiang","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.tips.2026.07.004_bb0105","doi-asserted-by":"crossref","first-page":"15085","DOI":"10.1021\/acs.jmedchem.5c01301","article-title":"Discovery of juglone derivatives as novel STAT3 inhibitors with potent suppression of cancer cell stemness against breast cancer","volume":"68","author":"Zhang","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2026.07.004_bb0110","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/s41419-022-05477-2","article-title":"Natural product preferentially targets redox and metabolic adaptations and aberrantly active STAT3 to inhibit breast tumor growth in vivo","volume":"13","author":"Zhu","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.tips.2026.07.004_bb0115","doi-asserted-by":"crossref","first-page":"7734","DOI":"10.1021\/acs.jmedchem.5b00686","article-title":"Hirsutinolide series inhibit Stat3 activity, modulate GCN1, MAP1B, Hsp105, G6PD, vimentin, and importin a-2 expression, and induce antitumor effects against human glioma","volume":"58","author":"Miklossy","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2026.07.004_bb0120","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.apsb.2024.10.001","article-title":"Dimeric natural product panepocyclinol A inhibits STAT3 via di-covalent modification","volume":"15","author":"Li","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.tips.2026.07.004_bb0125","doi-asserted-by":"crossref","first-page":"E95","DOI":"10.1002\/ajh.26084","article-title":"Targeting constitutively active STAT3 in chronic lymphocytic leukemia: a clinical trial of the STAT3 inhibitor pyrimethamine with pharmacodynamic analyses","volume":"96","author":"Brown","year":"2021","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.tips.2026.07.004_bb0130","doi-asserted-by":"crossref","first-page":"12373","DOI":"10.1021\/acs.jmedchem.3c00863","article-title":"Discovery, optimization, and evaluation of novel N-(benzimidazol-5-yl)-1,3,4-thiadiazol-2-amine analogues as potent STAT3 inhibitors for cancer treatment","volume":"66","author":"Wang","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2026.07.004_bb0135","doi-asserted-by":"crossref","first-page":"752","DOI":"10.3390\/biom16050752","article-title":"DB-2B, a novel and selective STAT3 inhibitor inhibits colorectal cancer progression in vitro and in vivo","volume":"16","author":"Chen","year":"2026","journal-title":"Biomolecules"},{"key":"10.1016\/j.tips.2026.07.004_bb0140","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1021\/acscentsci.3c01440","article-title":"Discovery of the highly selective and potent STAT3 inhibitor for pancreatic cancer treatment","volume":"10","author":"Chen","year":"2024","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.tips.2026.07.004_bb0145","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2025.36.e24","article-title":"Evaluating the specific STAT3 inhibitor YHO-1701 in ovarian cancer cell lines and patient-derived cell models: efficacy, mechanisms, and therapeutic potential","volume":"36","author":"Sato","year":"2025","journal-title":"J. Gynecol. Oncol."},{"key":"10.1016\/j.tips.2026.07.004_bb0150","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.3390\/cells13171463","article-title":"Stat3 inhibitors TTI-101 and SH5-07 suppress bladder cancer cell survival in 3D tumor models","volume":"13","author":"Singh","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.tips.2026.07.004_bb0155","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202400351","article-title":"Small molecule induces time-dependent inhibition of Stat3 dimerization and DNA-binding activity and regresses human breast tumor xenografts","volume":"25","author":"Yue","year":"2024","journal-title":"ChemBioChem"},{"key":"10.1016\/j.tips.2026.07.004_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215614","article-title":"SS-4 is a highly selective small molecule inhibitor of STAT3 tyrosine phosphorylation that potently inhibits GBM tumorigenesis in vitro and in vivo","volume":"533","author":"Wang","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.tips.2026.07.004_bb0165","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1186\/s12967-024-05542-8","article-title":"C188-9 reduces patient-specific primary breast cancer cells proliferation at the low, clinic-relevant concentration","volume":"22","author":"Zheng","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.tips.2026.07.004_bb0170","doi-asserted-by":"crossref","first-page":"15291","DOI":"10.1021\/acs.jmedchem.4c00872","article-title":"Natural product-inspired discovery of naphthoquinone-furo-piperidine derivatives as novel STAT3 inhibitors for the treatment of triple-negative breast cancer","volume":"67","author":"Fan","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2026.07.004_bb0175","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3390\/bioengineering10020159","article-title":"De novo design of imidazopyridine-tethered pyrazolines that target phosphorylation of STAT3 in human breast cancer cells","volume":"10","author":"Ravish","year":"2023","journal-title":"Bioengineering (Basel)"},{"key":"10.1016\/j.tips.2026.07.004_bb0180","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1021\/acsomega.3c10504","article-title":"Discovery of 2-pyrazolines that inhibit the phosphorylation of STAT3 as nanomolar cytotoxic agents","volume":"10","author":"Siddappa","year":"2025","journal-title":"ACS Omega"},{"key":"10.1016\/j.tips.2026.07.004_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215613","article-title":"Novel potent azetidine-based compounds irreversibly inhibit Stat3 activation and induce antitumor response against human breast tumor growth in vivo","volume":"534","author":"Yue","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.tips.2026.07.004_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2023.129565","article-title":"Azetidine ring, salicylic acid, and salicylic acid bioisosteres as determinants of the binding characteristics of novel potent compounds to Stat3","volume":"97","author":"Chen","year":"2024","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.tips.2026.07.004_bb0195","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202200039","article-title":"STAT protein thermal shift assays to monitor protein-inhibitor interactions","volume":"23","author":"Iliev","year":"2022","journal-title":"ChemBioChem"},{"key":"10.1016\/j.tips.2026.07.004_bb0200","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1021\/acsmedchemlett.4c00622","article-title":"Allosteric covalent inhibitors of the STAT3 transcription factor from virtual screening","volume":"16","author":"Szalai","year":"2025","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.tips.2026.07.004_bb0205","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/s41401-024-01261-4","article-title":"Novel STAT3 oligonucleotide compounds suppress tumor growth and overcome the acquired resistance to sorafenib in hepatocellular carcinoma","volume":"45","author":"Zhang","year":"2024","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.tips.2026.07.004_bb0210","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/j.ccell.2025.07.015","article-title":"Safety and efficacy of a STAT3-targeted cyclic oligonucleotide: from murine models to a phase 1 clinical trial in pet cats with oral cancer","volume":"43","author":"Grandis","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.tips.2026.07.004_bb0215","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.omtn.2022.06.012","article-title":"DNA minicircles as novel STAT3 decoy oligodeoxynucleotides endowed with anticancer activity in triple-negative breast cancer","volume":"29","author":"Casas","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.tips.2026.07.004_bb0220","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1021\/acs.biochem.5c00158","article-title":"Enhanced G-quadruplex stability and anticancer activity of N(2)-aryl deoxyguanosine-modified T40214 oligonucleotides targeting STAT3 in prostate cancer","volume":"64","author":"Choudhary","year":"2025","journal-title":"Biochemistry"},{"key":"10.1016\/j.tips.2026.07.004_bb0225","doi-asserted-by":"crossref","first-page":"593","DOI":"10.3390\/molecules29030593","article-title":"STAT3 decoy oligodeoxynucleotides suppress liver inflammation and fibrosis in liver cancer cells and a DDC-induced liver injury mouse model","volume":"29","author":"Choi","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.tips.2026.07.004_bb0230","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1158\/1078-0432.CCR-16-1317","article-title":"Inhibition of STAT3 with the generation 2.5 antisense oligonucleotide, AZD9150, decreases neuroblastoma tumorigenicity and increases chemosensitivity","volume":"23","author":"Odate","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tips.2026.07.004_bb0235","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac5272","article-title":"AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer","volume":"7","author":"Hong","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.tips.2026.07.004_bb0240","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ccell.2019.10.002","article-title":"A potent and selective small-molecule degrader of STAT3 achieves complete tumor regression in vivo","volume":"36","author":"Bai","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.tips.2026.07.004_bb0245","doi-asserted-by":"crossref","first-page":"11280","DOI":"10.1021\/acs.jmedchem.9b01530","article-title":"Structure-based discovery of SD-36 as a potent, selective, and efficacious PROTAC degrader of STAT3 protein","volume":"62","author":"Zhou","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2026.07.004_bb0250","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1021\/acsmedchemlett.1c00155","article-title":"SD-91 as A potent and selective STAT3 degrader capable of achieving complete and long-lasting tumor regression","volume":"12","author":"Zhou","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.tips.2026.07.004_bb0255","doi-asserted-by":"crossref","first-page":"20495","DOI":"10.1021\/acs.jmedchem.4c01946","article-title":"Discovery of SD-436: a potent, highly selective and efficacious STAT3 PROTAC degrader capable of achieving complete and long-lasting tumor regression","volume":"67","author":"Xu","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2026.07.004_bb0260","article-title":"Design, synthesis, and biological characterization of a potent STAT3 degrader for the treatment of gastric cancer","volume":"13","author":"Li","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.tips.2026.07.004_bb0265","doi-asserted-by":"crossref","first-page":"4872","DOI":"10.1039\/D5MD00260E","article-title":"Discovery of a potent and selective PROTAC degrader for STAT3","volume":"31","author":"Wang","year":"2025","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.tips.2026.07.004_bb0270","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.160606","article-title":"Small-molecule PROTAC mediates targeted protein degradation to treat STAT3-dependent epithelial cancer","volume":"7","author":"Jin","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.tips.2026.07.004_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117507","article-title":"Development of decoy oligonucleotide-warheaded chimeric molecules targeting STAT3","volume":"95","author":"Shih","year":"2023","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.tips.2026.07.004_bb0280","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41419-025-07535-x","article-title":"Decoy-PROTAC for specific degradation of \u201cundruggable\u201d STAT3 transcription factor","volume":"16","author":"Li","year":"2025","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.tips.2026.07.004_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102137","article-title":"Oligo-PROTAC strategy for cell-selective and targeted degradation of activated STAT3","volume":"35","author":"Hall","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.tips.2026.07.004_bb0290","first-page":"255","article-title":"Self-assembled PROTACs enable protein degradation to reprogram the tumor microenvironment for synergistically enhanced colorectal cancer immunotherapy","volume":"43","author":"Lu","year":"2025","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.tips.2026.07.004_bb0295","article-title":"A STAT3 degrader demonstrates pre-clinical efficacy in venetoclax resistant acute myeloid leukemia","author":"Chakraborty","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.tips.2026.07.004_bb0300","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1021\/acs.jmedchem.0c01705","article-title":"Discovery of novel azetidine amides as potent small-molecule STAT3 inhibitors","volume":"64","author":"Brotherton-Pleiss","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2026.07.004_bb0305","doi-asserted-by":"crossref","first-page":"5647","DOI":"10.3390\/cancers15235647","article-title":"Oligonucleotide-based therapeutics for STAT3 targeting in cancer-drug carriers matter","volume":"15","author":"Molenda","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.tips.2026.07.004_bb0310","doi-asserted-by":"crossref","first-page":"9524","DOI":"10.3390\/ijms24119524","article-title":"Structural and biological features of G-quadruplex aptamers as promising inhibitors of the STAT3 signaling pathway","volume":"24","author":"Esposito","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tips.2026.07.004_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102268","article-title":"Bi-functional CpG-STAT3 decoy oligonucleotide triggers multilineage differentiation of acute myeloid leukemia in mice","volume":"35","author":"Wang","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.tips.2026.07.004_bb0320","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s43556-022-00112-0","article-title":"An overview of PROTACs: a promising drug discovery paradigm","volume":"3","author":"Liu","year":"2022","journal-title":"Mol. Biomed."},{"key":"10.1016\/j.tips.2026.07.004_bb0325","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.tips.2024.07.003","article-title":"Targeting the STAT3 pathway with STAT3 degraders","volume":"45","author":"Wang","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.tips.2026.07.004_bb0330","doi-asserted-by":"crossref","first-page":"7391","DOI":"10.1073\/pnas.0609757104","article-title":"Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity","volume":"104","author":"Siddiquee","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2026.07.004_bb0335","doi-asserted-by":"crossref","DOI":"10.2217\/cns-2022-0005","article-title":"A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma","volume":"11","author":"de Groot","year":"2022","journal-title":"CNS Oncol."},{"key":"10.1016\/j.tips.2026.07.004_bb0340","article-title":"First-in-child phase I trial of p-STAT3 inhibitor WP1066 in pediatric brain tumor patients","volume":"11","author":"Castellino","year":"2025","journal-title":"JCI Insight"},{"key":"10.1016\/j.tips.2026.07.004_bb0345","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1158\/1078-0432.CCR-24-2920","article-title":"Phase I trial of TTI-101, a first-in-class oral inhibitor of STAT3, in patients with advanced solid tumors","volume":"31","author":"Tsimberidou","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tips.2026.07.004_bb0350","doi-asserted-by":"crossref","first-page":"OF1","DOI":"10.1158\/1078-0432.CCR-21-4021","article-title":"Randomized, double-blind, placebo-controlled phase III study of paclitaxel \u00b1 napabucasin in pretreated advanced gastric or gastroesophageal junction adenocarcinoma","volume":"28","author":"Shah","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tips.2026.07.004_bb0355","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.3390\/cancers14051330","article-title":"Ipilimumab, pembrolizumab, or nivolumab in combination with BBI608 in patients with advanced cancers treated at MD Anderson Cancer Center","volume":"14","author":"Vo","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.tips.2026.07.004_bb0360","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1007\/s10147-021-01987-9","article-title":"Phase I study of napabucasin in combination with FOLFIRI+bevacizumab in Japanese patients with metastatic colorectal cancer","volume":"26","author":"Taniguchi","year":"2021","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.tips.2026.07.004_bb0365","first-page":"100","article-title":"Napabucasin plus FOLFIRI in patients with previously treated metastatic colorectal cancer: results from the open-label, randomized phase III CanStem303C study","volume":"22","author":"Shah","year":"2023","journal-title":"Clin. Colorectal Cancer"},{"key":"10.1016\/j.tips.2026.07.004_bb0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101897","article-title":"Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial","volume":"58","author":"Bekaii-Saab","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.tips.2026.07.004_bb0375","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.clml.2020.12.012","article-title":"A phase 1b study to evaluate the safety and efficacy of durvalumab in combination with tremelimumab or danvatirsen in patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"21","author":"Ribrag","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.tips.2026.07.004_bb0380","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.1158\/1078-0432.CCR-22-2483","article-title":"Phase I study of acalabrutinib plus danvatirsen (AZD9150) in relapsed\/refractory diffuse large B-cell lymphoma including circulating tumor DNA biomarker assessment","volume":"29","author":"Roschewski","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tips.2026.07.004_bb0385","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s40265-017-0759-4","article-title":"Napabucasin: an update on the first-in-class cancer stemness inhibitor","volume":"77","author":"Hubbard","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.tips.2026.07.004_bb0390","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S2468-1253(18)30009-8","article-title":"Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial","volume":"3","author":"Jonker","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.tips.2026.07.004_bb0395","doi-asserted-by":"crossref","first-page":"6517","DOI":"10.1038\/s41598-021-85888-x","article-title":"LLL12B, a small molecule STAT3 inhibitor, induces growth arrest, apoptosis, and enhances cisplatin-mediated cytotoxicity in medulloblastoma cells","volume":"11","author":"Chen","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tips.2026.07.004_bb0400","article-title":"A novel small molecule LLL12B inhibits STAT3 signaling and sensitizes ovarian cancer cell to paclitaxel and cisplatin","volume":"16","author":"Zhang","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.tips.2026.07.004_bb0405","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.3390\/biom15071035","article-title":"Co-inhibition of PARP and STAT3 as a promising approach for triple-negative breast cancer","volume":"15","author":"Shi","year":"2025","journal-title":"Biomolecules"},{"key":"10.1016\/j.tips.2026.07.004_bb0410","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1111\/cas.14369","article-title":"Antitumor activity of a novel oral signal transducer and activator of transcription 3 inhibitor YHO-1701","volume":"111","author":"Nishisaka","year":"2020","journal-title":"Cancer Sci."},{"key":"10.1016\/j.tips.2026.07.004_bb0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116040","article-title":"WP1066, a small molecule inhibitor of STAT3, chemosensitizes paclitaxel-resistant ovarian cancer cells to paclitaxel by simultaneously inhibiting the activity of STAT3 and the interaction of STAT3 with Stathmin","volume":"221","author":"Yang","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.tips.2026.07.004_bb0420","doi-asserted-by":"crossref","DOI":"10.1590\/acb396624","article-title":"Effect of napabucasin and doxorubicin via the Jak2\/Stat3 signaling pathway in suppressing the proliferation of neuroblastoma cells","volume":"39","author":"\u00dcnl\u00fc","year":"2024","journal-title":"Acta Cir. Bras."},{"key":"10.1016\/j.tips.2026.07.004_bb0425","doi-asserted-by":"crossref","first-page":"544","DOI":"10.5603\/fm.103887","article-title":"Exploring apoptotic pathways in SH-SY5Y neuroblastoma cells: combined effects of napabucasin and doxorubicin","volume":"84","author":"\u00dcnl\u00fc","year":"2025","journal-title":"Folia Morphol. (Warsz)"},{"key":"10.1016\/j.tips.2026.07.004_bb0430","doi-asserted-by":"crossref","first-page":"350","DOI":"10.2174\/1574892816666210224155403","article-title":"STAT3 inhibitor napabucasin inhibits tumor growth and cooperates with proteasome inhibition in human ovarian cancer cells","volume":"16","author":"Liu","year":"2021","journal-title":"Recent Pat. Anticancer. Drug Discov."},{"key":"10.1016\/j.tips.2026.07.004_bb0435","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00280-020-04059-3","article-title":"Phase 1 study of napabucasin, a cancer stemness inhibitor, in patients with advanced solid tumors","volume":"85","author":"Kawazoe","year":"2020","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.tips.2026.07.004_bb0440","doi-asserted-by":"crossref","first-page":"933","DOI":"10.21873\/invivo.11561","article-title":"A phase I study of napabucasin plus paclitaxel for japanese patients with advanced\/recurrent gastric cancer","volume":"33","author":"Shitara","year":"2019","journal-title":"In Vivo"},{"key":"10.1016\/j.tips.2026.07.004_bb0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2026.114761","article-title":"NF-\u03baB and STAT3 signaling uniquely stratify survival in female glioblastoma patients","volume":"29","author":"Wong","year":"2026","journal-title":"iScience"},{"key":"10.1016\/j.tips.2026.07.004_bb0450","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1038\/s41467-019-11614-x","article-title":"A STAT3-based gene signature stratifies glioma patients for targeted therapy","volume":"10","author":"Tan","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tips.2026.07.004_bb0455","doi-asserted-by":"crossref","first-page":"44125","DOI":"10.1021\/acsomega.5c05380","article-title":"A multi-input deep learning architecture for STAT3 inhibitor prediction","volume":"10","author":"Liang","year":"2025","journal-title":"ACS Omega"},{"key":"10.1016\/j.tips.2026.07.004_bb0460","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1007\/s11030-024-11067-5","article-title":"Identification of STAT3 phosphorylation inhibitors using generative deep learning, virtual screening, molecular dynamics simulations, and biological evaluation for non-small cell lung cancer therapy","volume":"29","author":"Cai","year":"2025","journal-title":"Mol. Divers."},{"key":"10.1016\/j.tips.2026.07.004_bb0465","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-02444-7","article-title":"Interpretable prediction of drug synergy for breast cancer by random forest with features from Boolean modeling of signaling pathways","volume":"15","author":"Taoma","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tips.2026.07.004_bb0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2023.103091","article-title":"Chronic inflammation in high-fat diet-fed mice: unveiling the early pathogenic connection between liver and adipose tissue","volume":"139","author":"Bae","year":"2023","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.tips.2026.07.004_bb0475","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/ueg2.12736","article-title":"Gastrointestinal perforations associated with JAK inhibitors: a disproportionality analysis of the FDA adverse event reporting system","volume":"13","author":"Goldman","year":"2025","journal-title":"United Euro. Gastroenterol. J."}],"container-title":["Trends in Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614726001732?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614726001732?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T08:11:31Z","timestamp":1789027891000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165614726001732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":95,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0165614726001732"],"URL":"https:\/\/doi.org\/10.1016\/j.tips.2026.07.004","relation":{},"ISSN":["0165-6147"],"issn-type":[{"value":"0165-6147","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"STAT3 signaling inhibitors for cancer treatment","name":"articletitle","label":"Article Title"},{"value":"Trends in Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tips.2026.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}